Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical has updated and adopted revised terms of reference for its Board Audit Committee, effective 31 December 2025, to strengthen corporate governance and regulatory compliance. The revised framework clarifies that the Audit Committee, composed mainly of independent non-executive directors including at least one accounting professional, will exercise certain supervisory board powers under PRC Company Law, define stricter qualification and independence requirements for committee members, and set out clear responsibilities for the committee convener and mechanisms for filling vacancies, thereby reinforcing oversight of the company’s financial reporting and internal control for the benefit of investors and other stakeholders.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Co., Ltd. is a Hong Kong-listed pharmaceutical company based in the People’s Republic of China, operating in the healthcare industry with a focus on manufacturing and selling pharmaceutical products. The company is governed under PRC company law and Hong Kong Listing Rules, reflecting its dual focus on the domestic Chinese market and international capital markets.
Average Trading Volume: 2,147,224
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.88B
See more data about 0719 stock on TipRanks’ Stock Analysis page.